NOK 1.11
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on...
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is of fair value on EV/EBITDA.
Target Price
The average target price of BGBIO.OL is 1.9 and suggests 71% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
